67 related articles for article (PubMed ID: 18048768)
1. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice.
van Wanrooij EJ; de Jager SC; van Es T; de Vos P; Birch HL; Owen DA; Watson RJ; Biessen EA; Chapman GA; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):251-7. PubMed ID: 18048768
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies.
Piotrowska A; Rojewska E; Pawlik K; Kreiner G; Ciechanowska A; Makuch W; Zychowska M; Mika J
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3418-3437. PubMed ID: 30076959
[TBL] [Abstract][Full Text] [Related]
3. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.
Jenh CH; Cox MA; Cui L; Reich EP; Sullivan L; Chen SC; Kinsley D; Qian S; Kim SH; Rosenblum S; Kozlowski J; Fine JS; Zavodny PJ; Lundell D
BMC Immunol; 2012 Jan; 13():2. PubMed ID: 22233170
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptor CXCR3 promotes growth of glioma.
Liu C; Luo D; Reynolds BA; Meher G; Katritzky AR; Lu B; Gerard CJ; Bhadha CP; Harrison JK
Carcinogenesis; 2011 Feb; 32(2):129-37. PubMed ID: 21051441
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune cell recruitment in atherosclerosis.
Döring Y; van der Vorst EPC; Weber C
Nat Rev Cardiol; 2024 Apr; ():. PubMed ID: 38664575
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis.
Prapiadou S; Živković L; Thorand B; George MJ; van der Laan SW; Malik R; Herder C; Koenig W; Ueland T; Kleveland O; Aukrust P; Gullestad L; Bernhagen J; Pasterkamp G; Peters A; Hingorani AD; Rosand J; Dichgans M; Anderson CD; Georgakis MK
Circulation; 2024 Feb; 149(9):669-683. PubMed ID: 38152968
[TBL] [Abstract][Full Text] [Related]
7. Structure basis for the modulation of CXC chemokine receptor 3 by antagonist AMG487.
Jiao H; Pang B; Chiang YC; Chen Q; Pan Q; Ren R; Hu H
Cell Discov; 2023 Nov; 9(1):119. PubMed ID: 38012179
[No Abstract] [Full Text] [Related]
8. Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis.
Alluri SR; Higashi Y; Berendzen A; Grisanti LA; Watkinson LD; Singh K; Hoffman TJ; Carmack T; Devanny EA; Tanner M; Kil KE
EJNMMI Res; 2023 Jul; 13(1):67. PubMed ID: 37438543
[TBL] [Abstract][Full Text] [Related]
9. Hyperlipidaemia elicits an atypical, T helper 1-like CD4
van Os BW; Vos WG; Bosmans LA; van Tiel CM; Lith SC; den Toom MS; Beckers L; Levels JHM; van Wouw SAE; Zelcer N; Zaal EA; Berkers CR; van der Lest CHA; Helms JB; Weber C; Atzler D; de Winther MPJ; Baardman J; Lutgens E
Eur Heart J Open; 2023 Mar; 3(2):oead013. PubMed ID: 36969380
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis.
Alluri SR; Higashi Y; Berendzen A; Grisanti LA; Watkinson LD; Singh K; Hoffman TJ; Carmack T; Devanny EA; Tanner M; Kil KE
Res Sq; 2023 Feb; ():. PubMed ID: 36865232
[No Abstract] [Full Text] [Related]
11. Smooth Muscle Cell-Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location.
Xiang P; Blanchard V; Francis GA
Front Physiol; 2022; 13():921597. PubMed ID: 35795646
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Mediators in Atherosclerotic Vascular Remodeling.
Evans BR; Yerly A; van der Vorst EPC; Baumgartner I; Bernhard SM; Schindewolf M; Döring Y
Front Cardiovasc Med; 2022; 9():868934. PubMed ID: 35600479
[TBL] [Abstract][Full Text] [Related]
13. Where the Action Is-Leukocyte Recruitment in Atherosclerosis.
Mauersberger C; Hinterdobler J; Schunkert H; Kessler T; Sager HB
Front Cardiovasc Med; 2021; 8():813984. PubMed ID: 35087886
[TBL] [Abstract][Full Text] [Related]
14. Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential.
Márquez AB; van der Vorst EPC; Maas SL
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501271
[TBL] [Abstract][Full Text] [Related]
15. High Fat Diet-Induced CD8
Kiran S; Kumar V; Murphy EA; Enos RT; Singh UP
Front Immunol; 2021; 12():680944. PubMed ID: 34248964
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Cell Recruitment in Cardiovascular Disease.
Marchini T; Mitre LS; Wolf D
Front Cell Dev Biol; 2021; 9():635527. PubMed ID: 33681219
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory Chemokines in Atherosclerosis.
Gencer S; Evans BR; van der Vorst EPC; Döring Y; Weber C
Cells; 2021 Jan; 10(2):. PubMed ID: 33503867
[TBL] [Abstract][Full Text] [Related]
18. Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis.
Scheja L; Heeren J
Handb Exp Pharmacol; 2022; 270():289-310. PubMed ID: 33373032
[TBL] [Abstract][Full Text] [Related]
19. Cxcl9l and Cxcr3.2 regulate recruitment of osteoclast progenitors to bone matrix in a medaka osteoporosis model.
Phan QT; Tan WH; Liu R; Sundaram S; Buettner A; Kneitz S; Cheong B; Vyas H; Mathavan S; Schartl M; Winkler C
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19276-19286. PubMed ID: 32719141
[TBL] [Abstract][Full Text] [Related]
20. T cell subsets and functions in atherosclerosis.
Saigusa R; Winkels H; Ley K
Nat Rev Cardiol; 2020 Jul; 17(7):387-401. PubMed ID: 32203286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
